1RV1 | C:27-102; C:27-102; C:27-102 | CRYSTAL STRUCTURE OF HUMAN MDM2 WITH AN IMIDAZOLINE INHIBITOR |
1T4E | B:27-102; B:27-102 | STRUCTURE OF HUMAN MDM2 IN COMPLEX WITH A BENZODIAZEPINE INHIBITOR |
1T4F | M:27-102 | STRUCTURE OF HUMAN MDM2 IN COMPLEX WITH AN OPTIMIZED P53 PEPTIDE |
1YCR | A:27-102 | MDM2 BOUND TO THE TRANSACTIVATION DOMAIN OF P53 |
1Z1M | A:27-102 | NMR STRUCTURE OF UNLIGANDED MDM2 |
3JZK | A:27-102 | CRYSTAL STRUCTURE OF MDM2 WITH CHROMENOTRIAZOLOPYRIMIDINE 1 |
3JZR | A:27-102 | HUMAN MDM2 LIGANDED WITH A 12MER PEPTIDE INHIBITOR (PDI6W) |
3JZS | A:27-102 | HUMAN MDM2 LIGANDED WITH A 12MER PEPTIDE INHIBITOR (PDIQ) |
3LBL | E:27-102; E:27-102; E:27-102 | STRUCTURE OF HUMAN MDM2 PROTEIN IN COMPLEX WITH MI-63-ANALOG |
3LNJ | E:27-102; E:27-102; E:27-102 | CRYSTAL STRUCTURE OF HUMAN MDM2 IN COMPLEX WITH D-PEPTIDE INHIBITOR (DPMI-ALPHA) |
3LNZ | O:27-102; O:27-102; O:27-102; O:27-102; O:27-102; O:27-102; O:27-102; O:27-102 | CRYSTAL STRUCTURE OF HUMAN MDM2 WITH A 12-MER PEPTIDE INHIBITOR PMI (N8A MUTANT) |
2VYR | D:26-101; D:26-101; D:26-101; D:26-101 | STRUCTURE OF HUMAN MDM4 N-TERMINAL DOMAIN BOUND TO A SINGLE DOMAIN ANTIBODY |
3JZO | A:26-101 | HUMAN MDMX LIGANDED WITH A 12MER PEPTIDE (PDI) |
3JZP | A:26-101 | HUMAN MDMX LIGANDED WITH A 12MER PEPTIDE INHIBITOR (PDI6W) |
3JZQ | B:26-101; B:26-101 | HUMAN MDMX LIGANDED WITH A 12MER PEPTIDE INHIBITOR (PDIQ) |